More recently, Lin et al. also reported that CPT2 downregulation in HCC promoted tumorigenesis and chemoresistance to cisplatin, which further supports the beneficial effects of CPT2 downregulation for hepatocarcinogenesis [69]. The gene discussed is CPT2; the disease is hepatocellular carcinoma.